Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
3.330
-0.070 (-2.06%)
At close: Jul 18, 2025, 4:00 PM
3.500
+0.170 (5.11%)
After-hours: Jul 18, 2025, 6:25 PM EDT

Company Description

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma.

The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses.

Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corporation
Genelux logo
CountryUnited States
Founded2001
IPO DateJan 26, 2023
IndustryBiotechnology
SectorHealthcare
Employees24
CEOThomas Zindrick

Contact Details

Address:
2625 Townsgate Road, Suite 230
Westlake Village, California 91361
United States
Phone805 267 9889
Websitegenelux.com

Stock Details

Ticker SymbolGNLX
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$6.00
CIK Code0001231457
CUSIP Number36870H103
ISIN NumberUS36870H1032
SIC Code2834

Key Executives

NamePosition
Thomas Zindrick J.D.Chairman, Chief Executive Officer and President
Dr. Joseph Cappello Ph.D.Chief Technical Officer
Matthew Pulisic M.B.A.Chief Financial Officer and Principal Financial and Accounting Officer
Sean Ryder J.D.General Counsel and Corporate Secretary
Dr. Yong Yu Ph.D.Senior Vice President of Clinical Development
Prof. Paul Scigalla M.D., Ph.D.Chief Medical Officer
Ralph Smalling B.Sc.Vice President and Head of Regulatory Affairs

Latest SEC Filings

DateTypeTitle
Jul 11, 2025ARSFiling
Jul 11, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Jul 11, 2025DEF 14AOther definitive proxy statements
May 6, 202510-QQuarterly Report
Apr 29, 202510-K/A[Amend] Annual report
Mar 28, 2025S-8Securities to be offered to employees in employee benefit plans
Mar 28, 202510-KAnnual Report
Mar 25, 2025424B5Filing
Mar 25, 20258-KCurrent Report
Mar 25, 2025FWPFree Writing Prospectus